Rotavirus vaccine - International Medica Foundation

Drug Profile

Rotavirus vaccine - International Medica Foundation

Alternative Names: Rhesus reassortant tetravalent rotavirus vaccine - NIAID; Rhesus rotavirus vaccine reassortant - International Medica Foundation; Rotamune; RotaShield; Rotavirus - NIAID; Rotavirus vaccine rhesus reassortant tetravalent - NIAID; RRV-TV

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator National Institute of Allergy and Infectious Diseases
  • Developer International Medica Foundation; Shanghai BravoBio Co
  • Class Rotavirus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Rotavirus infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Rotavirus-infections(In neonates, Prevention) in China (PO)
  • 21 Jul 2015 Rotavirus vaccine is still in phase-II development for rotavirus infections
  • 09 Oct 2014 Rotavirus vaccine licensed to BravoVax worldwide, excluding USA, Europe and Japan, for the prevention of Rotavirus infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top